Comprehensive Physico-chemical and Functional Similarity Assessment Study of RGB-14-P and RGB-14-X Drug Products as Proposed Biosimilars to Denosumab Reference Products.

IF 6.9 2区 医学 Q1 IMMUNOLOGY
BioDrugs Pub Date : 2025-09-01 Epub Date: 2025-08-06 DOI:10.1007/s40259-025-00738-w
Ágnes Szonja Garai, Dániel Hüse, Ádám Fizil, Zsolt Zólyomi, Gábor Lehoczki, Andrea Kis, Zsuzsanna Kálmán-Szekeres, Viktor Háda
{"title":"Comprehensive Physico-chemical and Functional Similarity Assessment Study of RGB-14-P and RGB-14-X Drug Products as Proposed Biosimilars to Denosumab Reference Products.","authors":"Ágnes Szonja Garai, Dániel Hüse, Ádám Fizil, Zsolt Zólyomi, Gábor Lehoczki, Andrea Kis, Zsuzsanna Kálmán-Szekeres, Viktor Háda","doi":"10.1007/s40259-025-00738-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Denosumab is a fully human monoclonal antibody (IgG2) k subclass that targets and binds with high affinity and specificity to receptor activator of nuclear factor-κB ligand (RANKL). Gedeon Richter's denosumab RGB-14-P and RGB-14-X are proposed biosimilar drug products to the reference medicinal products Prolia<sup>®</sup> and Xgeva<sup>®</sup> (marketing authorisation holder: Amgen Europe B.V. in the European Union [EU] and Amgen Inc. in USA, respectively). The present study demonstrates the structural, physico-chemical and functional similarity between RGB-14 and reference drug products marketed in the EU and US.</p><p><strong>Methods: </strong>Using an extensive, state-of-the-art analytical and functional panel of 38 methods ensured the comprehensive characterisation of the biosimilar and reference drug products. To assess biosimilarity, physico-chemical and biological functional tests were performed using multiple orthogonal techniques, in addition to the in-depth comparison of the primary and higher-order structures of the therapeutic proteins.</p><p><strong>Results: </strong>It has been demonstrated that the primary and higher order structures of RGB-14-P and RGB-14-X drug products are identical or highly similar to those of EU/US Prolia<sup>®</sup> and Xgeva<sup>®</sup>. The purity profiles of the biosimilar and reference products were similar. Only minor differences were observed in glycosylation patterns and charge variant profiles. A wide range of bioassays was used demonstrating similarity in terms of potency, ligand and receptor binding. Additionally, during comprehensive analysis of the reference product data as the function of expiry dates, shifts were revealed in certain quality parameters, although these did not impact the biological activity of the products.</p><p><strong>Conclusion: </strong>The extensive analytical and functional similarity assessment study provides robust evidence that the structure and function of RGB-14-P and RGB-14-X are highly similar to those of EU/US Prolia<sup>®</sup> and Xgeva<sup>®</sup>.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"697-724"},"PeriodicalIF":6.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354141/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioDrugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40259-025-00738-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Denosumab is a fully human monoclonal antibody (IgG2) k subclass that targets and binds with high affinity and specificity to receptor activator of nuclear factor-κB ligand (RANKL). Gedeon Richter's denosumab RGB-14-P and RGB-14-X are proposed biosimilar drug products to the reference medicinal products Prolia® and Xgeva® (marketing authorisation holder: Amgen Europe B.V. in the European Union [EU] and Amgen Inc. in USA, respectively). The present study demonstrates the structural, physico-chemical and functional similarity between RGB-14 and reference drug products marketed in the EU and US.

Methods: Using an extensive, state-of-the-art analytical and functional panel of 38 methods ensured the comprehensive characterisation of the biosimilar and reference drug products. To assess biosimilarity, physico-chemical and biological functional tests were performed using multiple orthogonal techniques, in addition to the in-depth comparison of the primary and higher-order structures of the therapeutic proteins.

Results: It has been demonstrated that the primary and higher order structures of RGB-14-P and RGB-14-X drug products are identical or highly similar to those of EU/US Prolia® and Xgeva®. The purity profiles of the biosimilar and reference products were similar. Only minor differences were observed in glycosylation patterns and charge variant profiles. A wide range of bioassays was used demonstrating similarity in terms of potency, ligand and receptor binding. Additionally, during comprehensive analysis of the reference product data as the function of expiry dates, shifts were revealed in certain quality parameters, although these did not impact the biological activity of the products.

Conclusion: The extensive analytical and functional similarity assessment study provides robust evidence that the structure and function of RGB-14-P and RGB-14-X are highly similar to those of EU/US Prolia® and Xgeva®.

RGB-14-P和RGB-14-X作为Denosumab参考产品生物类似药的综合理化和功能相似性评估研究
背景与目的:Denosumab是一种全人源单克隆抗体(IgG2) k亚类,以高亲和力和特异性靶向核因子-κB配体受体激活因子(RANKL)并结合。Gedeon Richter的denosumab RGB-14-P和RGB-14-X是参考药品Prolia®和Xgeva®(上市许可持有人分别为欧盟的Amgen Europe B.V.和美国的Amgen Inc.)的拟议生物仿制药。本研究证明了RGB-14与在欧盟和美国上市的参比药在结构、理化和功能上的相似性。方法:采用广泛的,最先进的38种方法的分析和功能面板,确保生物仿制药和参比药产品的全面表征。为了评估生物相似性,除了对治疗蛋白的一级和高阶结构进行深入比较外,还使用多种正交技术进行了物理化学和生物功能测试。结果:RGB-14-P和RGB-14-X的一级和高阶结构与EU/US Prolia®和Xgeva®完全相同或高度相似。该生物仿制药与参比产品的纯度谱相似。在糖基化模式和电荷变异谱上只观察到微小的差异。广泛的生物测定被用来证明在效力,配体和受体结合方面的相似性。此外,在综合分析参考产品数据作为有效期函数时,揭示了某些质量参数的变化,尽管这些变化并不影响产品的生物活性。结论:广泛的分析和功能相似性评估研究提供了强有力的证据,证明RGB-14-P和RGB-14-X的结构和功能与EU/US Prolia®和Xgeva®高度相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BioDrugs
BioDrugs 医学-免疫学
CiteScore
12.60
自引率
2.90%
发文量
50
审稿时长
>12 weeks
期刊介绍: An essential resource for R&D professionals and clinicians with an interest in biologic therapies. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信